ScreenerHero

MGNX MacroGenics, Inc.

NAS · US · Healthcare · Biotechnology · macrogenics.com
3.550USD-2.47%Mkt Cap: 226.14M $P/E: —

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pip…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap226.14M USD
Enterprise Value93.97M USD
Revenue (TTM)175.14M USD
Gross Profit113.49M USD
Net Income (TTM)-74.62M USD
Revenue/Share2.76 USD
Last Price3.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.48
PEG—
EV/EBITDA-2.92
EV/Revenue0.54
P/S1.32
P/B5.40
EPS (TTM)-1.64
EPS (Forward)-1.47
52W Range
1.29060% of range5.080
52W High5.080 USD
52W Low1.290 USD
Profitability
Gross Margin75.91%
Oper. Margin-42.19%
EBITDA Margin-18.37%
Profit Margin-49.91%
ROE-134.23%
ROA-29.05%
Growth
Revenue Growth378.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.04M USD
CapEx (TTM)1.91M USD
FCF Margin-39.63%
FCF Yield-30.69%
Net Debt-138.21M USD
Net Debt/EBITDA4.30
Balance Sheet
Debt/Equity0.66
Current Ratio2.96
Quick Ratio2.92
Book Value/Sh0.67 USD
Cash/Share2.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.000 USD
Upside (mean)+125.4%
Target Range4.000 USD – 11.00 USD
4.000+125.4% to mean11.00
# Analysts4
Ownership
Shares Out.63.70M
Float56.42M
Insiders3.48%
Institutions77.62%
Short Interest
Short Ratio16.2d
Short % Float11.44%
Short % Out.11.04%
Shares Short7.03M
Short (prev mo.)7.26M
Technical
SMA 504.002 (-11.3%)
SMA 2003.277 (+8.3%)
Beta1.21
S&P 52W Chg16.45%
Avg Vol (30d)522.36K
Avg Vol (10d)748.40K
Technical Indicators
RSI (14)40.1
MACD-0.1272
MACD Signal-0.0898
MACD Hist.-0.0373
BB Upper4.365 USD
BB Middle3.909 USD
BB Lower3.454 USD
BB Width23.32%
ATR (14)0.2380 USD
Vol Ratio (20d)0.92x